Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 15OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Melanoma 1Brain Neoplasms 1

Interventions

Cyclophosphamide 548pembrolizumab 384Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Has results × Tiragolumab × Clear all
NCT05746481 2026-01-22

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

University of Pittsburgh

Phase 2 Terminated
3 enrolled 12 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03977467 2025-08-27

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

SCRI Development Innovations, LLC

Phase 2 Completed
46 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05060003 2024-02-20

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Washington University School of Medicine

Phase 2 Terminated
7 enrolled 4 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡